ArticleJournal of translational medicine2025
Unraveling the role of MAG, PTEN, and NOTCH1 in axonal regeneration: a network analysis and molecular dynamics study of siRNA/drugs/nanocarriers interactions.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAxonal regeneration remains a critical yet challenging process in spinal cord injury (SCI) recovery, primarily due to the limited regenerative capacity of adult central nervous system (CNS) axons. Identifying key molecular targets and optimizing therapeutic delivery systems are promising strategies to enhance axonal regeneration.
methodsIn this study, we investigated the roles of three critical proteins-MAG, PTEN, and NOTCH1-in axonal regeneration through an integrative approach combining network analysis and molecular dynamics (MD) simulations. We compiled 361 regeneration-associated genes from the REGene database and a targeted PubMed literature review. Gene ontology enrichment analysis via DAVID identified key genes linked to axonal regeneration and oligodendrocyte differentiation. A protein-protein interaction (PPI) network was constructed to pinpoint hub genes, with Cytoscape used to assess degree, betweenness, and closeness centrality. The top-ranking genes across at least two centrality metrics were selected, and GeneMANIA validated their functional relevance, confirming MAG, PTEN, and NOTCH1 as negative regulators of regeneration. Using siDirect and siRNA Wizard, we designed siRNA molecules targeting these genes, while DGIdb and literature mining identified small-molecule drugs (e.g., GT1b for MAG, enzalutamide for PTEN). MD simulations explored their interactions with polymeric nanocarriers-PLGA, PEI, chitosan, and PEI-PEG-revealing distinct binding patterns.
resultsAll proteins exhibited favorable binding with their respective drugs, with MAG-GT1b demonstrating the strongest affinity ( -146.07 ± 61.63 kJ/mol). Free energy landscape (FEL) analysis of the MAG/GT1b complex revealed a pronounced global energy minimum at 20.6 kJ/mol, reflecting high-affinity binding. Among nanocarriers, chitosan showed strong siRNA interactions, whereas PLGA and PEI exhibited superior drug-binding properties, particularly for GT1b, as evidenced by lower solvent-accessible surface area (SASA) values, indicating tighter encapsulation. Notably, PLGA-based systems displayed a broader radius of gyration (Rg) distribution, attributed to their amphiphilic nature, which promotes rapid self-assembly into multiple dispersed nanocarriers rather than consolidated structures. Additionally, PLGA chains exhibited reduced average SASA values (40-90 nm
conclusionsThe strongest siRNA interactions occurred between PTEN siRNA-enzalutamide and PLGA ( -107.31 kJ/mol) or PEI ( -87.15 kJ/mol), primarily driven by van der Waals forces. While these in silico findings are promising, preclinical validation is essential for clinical translation. This study highlights the potential of combining network analysis and MD simulations to decipher complex interactions among proteins, siRNA, drugs, and polymers, offering novel insights into therapeutic strategies for SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.